EUVIMEDEUVIMED entdecken
Open Access

A novel small molecule inhibitor of p38⍺ MAP kinase augments cardiomyocyte cell cycle entry in response to direct cell cycle stimulation

Riham R E Abouleisa iD, Jessica M Miller, Ahmad Gebreil, Abou Bakr M Salama, Marc Dwenger, Hania Abdelhafez, Reham M Wahid, Adeniyi T Adewumi, Mahmoud E S Soliman, Nader E Abo-Dya, Tamer M A Mohamed iD

British Journal of Pharmacology · 2023

DOI: 10.1111/bph.16209 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2023. Verfasst von Riham R E Abouleisa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Cardiology, Division of Cardiovascular Medicine, Department of Medicine, University of Louisville, Louisville, Kentucky, USA. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Enzyme Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIEHS NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Myocardial infarction (MI) is the leading cause of mortality globally due in part to the limited ability of cardiomyocytes (CMs) to regenerate. Recently, we demonstrated that overexpression of four‐cell cycle factors, CDK1, CDK4, cyclin B1 and cyclin D1 (4F), induced cell division in ~20% of the post‐mitotic CMs overexpressed 4F. The current study aims to identify a small molecule that augments 4F‐induced CM cycle induction. Experimental Approach, Key Results Screening of small molecules with a potential to augment 4F‐induced cell‐cycle induction in 60‐day‐old mature human induced pluripotent cardiomyocytes (hiPS‐CMs) revealed N‐(4,6‐Dimethylpyridin‐2‐yl)‐4‐(pyridine‐4‐yl)piperazine‐1‐carbothioamide (NDPPC), which activates cell cycle progression in 4F‐transduced hiPS‐CMs. Autodock tool and Autodock vina computational methods showed that NDPPC has a potential interaction with the binding site at the human p38⍺ mitogen‐activated protein kinase (p38⍺ MAP kinase), a critical negative regulator of the mammalian cell cycle. A p38 MAP kinase activity assay showed that NDPPC inhibits p38⍺ with 5–10 times lower IC 50 compared to the other P38 isoforms in a dose‐dependent manner. Overexpression of p38⍺ MAP kinase in CMs inhibited 4F cell cycle induction, and treatment with NDPPC reversed the cell cycle inhibitory effect. Conclusion and Implications NDPPC is a novel inhibitor for p38 MAP kinase and is a promising drug to augment CM cell cycle response to the 4F. NDPPC could become an adjunct treatment with other cell cycle activators for heart failure treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocytes, CardiacEnzyme InhibitorsAnimalsHumansMitogen-Activated Protein KinasesCell CycleCell Divisionp38 Mitogen-Activated Protein KinasesMammalsPhosphorylcholine

Stichwörter der Autor:innen

P38autodockcardiomyocytecell cyclecyclinheartproliferationsmall molecule

Substanzen

Enzyme InhibitorsMitogen-Activated Protein Kinasesp38 Mitogen-Activated Protein KinasesN-decylphosphorylcholinePhosphorylcholine

Autor:innen und Institutionen

  • Institute of Molecular Cardiology, Division of Cardiovascular Medicine, Department of Medicine, University of Louisville, Louisville, Kentucky, USA.
  • Department of Cardiovascular Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
  • Physiology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
  • Molecular Bio-computation and Drug Design Laboratory, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia.
  • Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.

ORCID-Profile: Riham R E Abouleisa, Tamer M A Mohamed

Förderung

  • NHLBI NIH HHS
  • NIEHS NIH HHS
  • NIGMS NIH HHS
  • National Center for Advancing Translational Sciences
  • American Heart Association

Zitieren

APA

Abouleisa, R. R. E., Miller, J. M., Gebreil, A., Salama, A. B. M., Dwenger, M., Abdelhafez, H., Wahid, R. M., Adewumi, A. T., Soliman, M. E. S., Abo-Dya, N. E., & Mohamed, T. M. A. (2023). A novel small molecule inhibitor of p38⍺ MAP kinase augments cardiomyocyte cell cycle entry in response to direct cell cycle stimulation. British Journal of Pharmacology. https://doi.org/10.1111/bph.16209

Vancouver

Abouleisa RRE, Miller JM, Gebreil A, Salama ABM, Dwenger M, Abdelhafez H, et al. A novel small molecule inhibitor of p38⍺ MAP kinase augments cardiomyocyte cell cycle entry in response to direct cell cycle stimulation. British Journal of Pharmacology. 2023. doi:10.1111/bph.16209

BibTeX
@article{Abouleisa2023,
  author = {Abouleisa, Riham R E and Miller, Jessica M and Gebreil, Ahmad and Salama, Abou Bakr M and Dwenger, Marc and Abdelhafez, Hania and Wahid, Reham M and Adewumi, Adeniyi T and Soliman, Mahmoud E S and Abo-Dya, Nader E and Mohamed, Tamer M A},
  title = {A novel small molecule inhibitor of p38⍺ MAP kinase augments cardiomyocyte cell cycle entry in response to direct cell cycle stimulation},
  journal = {British Journal of Pharmacology},
  year = {2023},
  doi = {10.1111/bph.16209}
}
Kostenlos starten →